

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Grand Pharmaceutical Group Limited

遠大醫藥集團有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

PROFIT ALERT

This announcement is made by Grand Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of the directors (the “**Board**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the information currently available to the Company and the preliminary review by the management of the Company over the unaudited management accounts of the Group for the six months ended 30 June 2022, it is expected that

- (i) for the six months ended 30 June 2022, if excluding the changes in fair value of investment in Telix Pharmaceuticals Limited (the “**Telix**”), the consolidated net profit attributable to owners of the Company increased by not less than 20% as compared with the same period of last year, due to further expansion in markets of the Group’s core products; and
- (ii) after considering the loss from changes in fair value of investment in Telix due to the decrease of its share price, it is expected that the consolidated net profit attributable to owners of the Company recorded a decrease of approximately 35%-45% as compared to that of the six months ended 30 June 2021 (the unaudited consolidated net profit attributable to owners of the Company for the six months ended 30 June 2021 amounted to approximately HK\$1,202,543,000, in which including gain from changes in fair value of investment in Telix amounted to approximately HK\$294.79 million). As the date of this announcement, the share price of Telix has increased by more than 72% as compared with the share price as at 30 June 2022 and recovered to the share price higher than that as at 31 December 2021, and the impact to the Group is substantially decreased. Furthermore, our management did not notify any obvious substantial adverse impact to the operation of the Group during the current period.

The information contained in this announcement is only based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2022 and

the information currently available to the Board, and such information has not been reviewed by the Company's auditors or audit committee. The unaudited consolidated financial results of the Group for the six months ended 30 June 2022 have not been finalized and may be subject to adjustment. The announcement on the unaudited results of the Group for the six months ended 30 June 2022 is expected to be published in the middle of August 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 5 August 2022

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Dr. Shao Yan, Dr. Niu Zhanqi and Dr. Shi Lin, and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*